Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 22 Aug 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 20 May 2016 Planned number of patients changed from 15 to 63.